PMID- 26142341
OWN - NLM
STAT- MEDLINE
DCOM- 20160719
LR  - 20181113
IS  - 1993-0402 (Electronic)
IS  - 1672-0415 (Linking)
VI  - 21
IP  - 9
DP  - 2015 Sep
TI  - Effect of Danlou Tablet () on peri-procedural myocardial injury among patients 
      undergoing percutaneous coronary intervention for non-ST elevation acute coronary 
      syndrome: A study protocol of a multicenter, randomized, controlled trial.
PG  - 662-6
LID - 10.1007/s11655-015-2284-1 [doi]
AB  - BACKGROUND: It has been shown that administration of statins reduced the risk of 
      peri-procedural myocardial damage. However, it remains unclear whether Chinese 
      medicine Danlou Tablet (), similar to statins, may protect patients undergoing 
      percutaneous coronary intervention (PCI) from peri-procedural myocardial damage. 
      OBJECTIVE: To demonstrate the hypothesis whether treatment with Danlou Tablet 
      would improve clinical outcome in patients undergoing selective PCI with non-ST 
      elevation acute coronary syndrome (NSTE-ACS) in China. METHODS: Approximately 220 
      patients with unstable angina or non-ST-segment elevation myocardial infarction 
      undergoing PCI will be enrolled and randomized to Danlou Tablet treatment (4.5 
      g/day for 2 days before intervention, with a further 4.5 g/day for 90 days 
      thereafter) or placebo. All patients will not receive Danlou Tablet before 
      procedure. The primary end point is to evaluate the incidence of cardiac death, 
      myocardial infarction or unplanned re-hospitalization and revascularization after 
      30 days in patients undergoing selective PCI treated with Danlou Tablet compared 
      with placebo. Secondary endpoints include the incidence of peri-procedural 
      myocardial injury, 3-month clinical outcomes, the quality of life and Chinese 
      medicine syndromes assessment. CONCLUSION: This study protocol will provide 
      important evidence of Danlou Tablet treatment on the peri-procedural myocardial 
      injury in patients with NSTE-ACS undergoing selective PCI, which may support a 
      strategy of routine Danlou Tablet therapy to improve the clinical outcomes.
FAU - Wang, Lei
AU  - Wang L
AD  - The Second Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, 510405, China.
AD  - Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, 510120, 
      China.
FAU - Mao, Shuai
AU  - Mao S
AD  - The Second Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, 510405, China.
AD  - Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, 510120, 
      China.
FAU - Qi, Jian-yong
AU  - Qi JY
AD  - Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, 510120, 
      China.
FAU - Ren, Yi
AU  - Ren Y
AD  - Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, 510120, 
      China.
FAU - Guo, Xin-feng
AU  - Guo XF
AD  - The Second Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, 510405, China.
AD  - Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, 510120, 
      China.
FAU - Chen, Ke-ji
AU  - Chen KJ
AD  - Department of Cardiovascular Disease, Xiyuan Hospital, Chinese Academy of Chinese 
      Medical Sciences, Beijing, 100091, China.
FAU - Zhang, Min-zhou
AU  - Zhang MZ
AD  - The Second Clinical Medical College, Guangzhou University of Chinese Medicine, 
      Guangzhou, 510405, China. minzhouzhang@aliyun.com.
AD  - Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, 510120, 
      China. minzhouzhang@aliyun.com.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20150704
PL  - China
TA  - Chin J Integr Med
JT  - Chinese journal of integrative medicine
JID - 101181180
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Acute Coronary Syndrome/*diagnostic imaging/*drug therapy
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - *Electrocardiography
MH  - Endpoint Determination
MH  - Humans
MH  - Myocardium/*pathology
MH  - *Percutaneous Coronary Intervention
MH  - Sample Size
MH  - Ultrasonography
OTO - NOTNLM
OT  - Chinese medicine
OT  - Danlou Tablet
OT  - non-ST-segment elevation acute coronary syndrome
OT  - percutaneous coronary intervention
OT  - peri-procedural myocardial infarction
EDAT- 2015/07/05 06:00
MHDA- 2016/07/20 06:00
CRDT- 2015/07/05 06:00
PHST- 2014/10/20 00:00 [received]
PHST- 2015/07/05 06:00 [entrez]
PHST- 2015/07/05 06:00 [pubmed]
PHST- 2016/07/20 06:00 [medline]
AID - 10.1007/s11655-015-2284-1 [pii]
AID - 10.1007/s11655-015-2284-1 [doi]
PST - ppublish
SO  - Chin J Integr Med. 2015 Sep;21(9):662-6. doi: 10.1007/s11655-015-2284-1. Epub 
      2015 Jul 4.